Astellas expecting strong Xtandi growth as currency boosts 1Q
This article was originally published in Scrip
Executive Summary
Following its launch in the US last September, Astellas is forecasting rapid growth for Xtandi (enzalutamide) in what is set to be the prostate cancer drug's largest single market. Although sales were a modest at $82m (JPY8.5bn) in the Japanese firm's fiscal first quarter, they are expected to top $400m (JPY40.0bn) for the full year ending next 31 March as promotional efforts gather steam.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.